Abstract

The 2nd ICB conference in the series aims to build on the success of the inaugural 2013 event with an expanded scope which includes a review of the state-of-the-art technologies and emerging trends in upstream, downstream, and drug product unit operations. Topics such as facility design, financial modeling, control strategies, and quality and regulatory considerations will also be discussed. The ICB conference is intended to assemble a selected group of leading scientists and engineers from both academia and industry who are actively engaged in or are considering continuous bioprocessing.